Efficacy and Safety of SPARC0921 in Subjects With Spasticity

• Status: Completed
• Trial end date: 2017-08-25
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess whether SPARC0921 demonstrate efficacy and safety in the treatment of spasticity.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Pharma Advanced Research Company Limited

Criteria

Inclusion Criteria:

• Men and women age 18 years and older

• Able and willing to comply with the protocol, including availability for a scheduled clinic visits

• Willingness and giving of written informed consent

Exclusion Criteria:

• In relapse or history of unstable course over the prior 30 days prior to the Screening Visit

• Concomitant neurologic conditions causing spasticity

• Has received an investigational drug or device within 30 days that would interfere with the study goals prior to the Screening Visit

• Unable to comply with study procedures in the opinion of the investigator